Astria Therapeutics (ATXS) to Release Earnings on Wednesday

Astria Therapeutics (NASDAQ:ATXS) is expected to be announcing its Q3 2025 results before the market opens on Wednesday, November 12th. Analysts expect the company to announce earnings of ($0.42) per share and revenue of $10.6670 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Wednesday, November 19, 2025 at 4:00 PM ET.

Astria Therapeutics (NASDAQ:ATXS) last released its quarterly earnings results on Tuesday, August 12th. The biotechnology company reported ($0.57) EPS for the quarter, beating the consensus estimate of ($0.61) by $0.04. On average, analysts expect Astria Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Astria Therapeutics Stock Performance

Shares of Astria Therapeutics stock opened at $12.51 on Monday. The company has a market capitalization of $706.00 million, a P/E ratio of -6.22 and a beta of 0.21. Astria Therapeutics has a 1 year low of $3.56 and a 1 year high of $12.72. The company’s fifty day moving average is $9.31 and its two-hundred day moving average is $6.97.

Institutional Investors Weigh In On Astria Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of ATXS. XTX Topco Ltd acquired a new position in shares of Astria Therapeutics during the 2nd quarter worth $194,000. Bank of America Corp DE lifted its stake in shares of Astria Therapeutics by 24.9% in the second quarter. Bank of America Corp DE now owns 49,628 shares of the biotechnology company’s stock valued at $266,000 after purchasing an additional 9,881 shares during the period. PDT Partners LLC boosted its holdings in Astria Therapeutics by 90.3% during the second quarter. PDT Partners LLC now owns 54,642 shares of the biotechnology company’s stock worth $293,000 after buying an additional 25,935 shares in the last quarter. American Century Companies Inc. grew its position in Astria Therapeutics by 8.3% during the second quarter. American Century Companies Inc. now owns 56,442 shares of the biotechnology company’s stock worth $303,000 after buying an additional 4,335 shares during the period. Finally, Hsbc Holdings PLC increased its holdings in Astria Therapeutics by 85.5% in the second quarter. Hsbc Holdings PLC now owns 60,851 shares of the biotechnology company’s stock valued at $335,000 after buying an additional 28,043 shares in the last quarter. Institutional investors and hedge funds own 98.98% of the company’s stock.

Analyst Ratings Changes

ATXS has been the topic of a number of research reports. JMP Securities reissued a “market perform” rating on shares of Astria Therapeutics in a report on Wednesday, October 15th. Jefferies Financial Group cut Astria Therapeutics from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $30.00 to $13.00 in a research report on Tuesday, October 14th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $49.00 target price on shares of Astria Therapeutics in a research note on Wednesday, September 17th. Citigroup restated an “outperform” rating on shares of Astria Therapeutics in a research note on Wednesday, August 13th. Finally, Wedbush set a $13.00 price target on Astria Therapeutics and gave the stock a “neutral” rating in a report on Wednesday, October 15th. Three research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Astria Therapeutics has an average rating of “Hold” and a consensus price target of $25.00.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.